Prognostic significance of bcl-2 protein expression in aggressive Non-Hodgkin's Lymphoma

Blood

Volumn 87, Issue 1, 1996, Pages 265-272

  Hermine, Olivier ^b   Haioun, Corinne ^b   Lepage, Eric ^b   D'Agay, Marie Françoise ^b   Briere, Josette ^b   Lavignac, Caroline ^b   Fillet, Georges ^b   Salles, Gilles ^b   Marolleau, Jean Pierre ^b   Diebold, Jacques ^b   Reyes, Felix ^b   Gaulard, Philippe ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PROTEIN BCL 2; TUMOR MARKER; VINDESINE;

ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIFE TABLES; LYMPHOMA, HIGH-GRADE; LYMPHOMA, INTERMEDIATE-GRADE; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK; TUMOR MARKERS, BIOLOGICAL; VINDESINE;

EID: 0030029443     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.1.265.bloodjournal871265     Document Type: Article

References (47)

1. Tsujimoto T, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning the chromosome breakpoint of neoplastic B-cells with the t(14; 18) chromosome translocation. Science 226:1097, 1984
2. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
3. Cleary ML, Sklar J: Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439, 1985
4. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY: The 14;18 translocation in European cases of follicular lymphoma: Comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 76:58, 1990
5. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theoiogides A, Arnesen M: Multiple recurrent genomic defects in follicular lymphoma. N Engl J Med 316:79, 1987
6. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14; 18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185, 1987
7. Jacobson J, Wilkes B, Kwaiatkowski D, Medeiros L, Aisenberg A, Harris N: Bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features. Cancer 72:231, 1993
8. Pezzela F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY: Expression of the bcl-2 oncogene protein is not specific for the 14-18 chromosomal translocation. Am J Pathol 137:225, 1990
9. Gaulard P, d'Agay MF, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P, Diebold J, Mason DY: Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140:1089, 1992
10. Zutter M, Hockenberry D, Silverman GA, Korsmeyer SJ: Immunolocalization of the Bcl-2 protein within hematopoietic neoplasms. Blood 78:1062, 1991
11. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: Bcl-2 protein in non small-cell lung carcinoma. N Engl J Med 329:690, 1993
12. Nathan B, Anbazhagan R, Dyer M: Expression of bcl-2 like immunoreactivity in breast cancer. Breast 2:134, 1993
13. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Besnon M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 143:390, 1993
14. Charlotte F, L'Hermine A, Martin N, Geleyn Y, Nollet M, Gaulard P, Zafrani ES: Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 144:460, 1994
15. Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer S: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961, 1991
16. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80:879, 1992
17. Nunez G, London I, Hockenberry D, Alexander M, McKearn JP, Korsmeyer SJ: Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602, 1990
18. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, Mc.Kearn JP, Korsmeyer SJ: Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79, 1989
19. Bissonnette RP, Echeverri F, Mahboubi A, Green DR: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552, 1992
20. Eastman A: Activation of programmed cell death by anti cancer agents. Cisplatin as a model system. Cancer Cells 2:275, 1990
21. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cispiatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353, 1990
22. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
23. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticosteroids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
24. Campos L, Rouault JP, Sabido O, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
25. Pezzela F, Jones M, Ralfkier E, Ersboll J, Gatter KC, Mason DY: Evaluation of bcl-2 protein expression and 14; 18 translocation as prognostic markers in follicular lymphoma. Br J Cancer 65:87, 1992
26. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S: Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 12:149, 1994
27. Piris M, Pezzela F, Martinez-Montero JC, Orradre J, Villuendas R, Sanchez-Beato M, Cuena R, Cruz M, Martinez B, Garrido M, Gatter K, Aiello A, Delia D, Giardini, Rilke F: P53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337, 1994
28. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H, Morel P, Nouvel C, Herbrecht R, d'Agay MF, Gaulard P, Reyes F: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate and high grade non-Hodgkan's lymphoma in first complete remission. A study of 464 patients: J Clin Oncol, 12:2543, 1994
29. Tilly H, Coiffier B, Brice P, Sebban C, Bosly A, Lederlin P, Biron P, Dupriez B, Bordessoule D, Lepage E, d'Agay MF, Reyes F, Gisselbrecht C: Localized low-bulk aggressive lymphomas treated with chemotherapy alone in the LNH-87 protocol group 1. A GELA study. Fifth International Conference on Malignant Lymphoma, June 1993, p 98 (abstr)
30. Bosly A, Lepage E, Coiffier B, Dupriez B, Herbrecht R, Fillet G, Diviné M, Nouvel C, Tilly H, Bordessoule D, Gaulard P, Gisselbrecht C: Alternating chemotherapy does not improve results in poor prognosis aggressive lymphomas. LNH87 protocol group 3: A GELA study. Blood 82:554, 1993 (abstr)
31. Non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112, 1982
32. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, Van Unnik J, Mioduszewska O, Wright D. Updated kiel classification for lymphomas. Lancet 1:292, 1988
33. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive NHL: The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 329:987, 1993
34. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018, 1989
35. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:157, 1958
36. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
37. Cox DR, Oakes D: Analysis of survival data. New York, NY, Chapman & Hall, 1984
38. Yunis JJ, Mayer MG, Arnesen MA: Bcl-2 and other genomic alterations in the prognosis of large cell lymphoma. N Engl J Med 320:1047, 1989
39. Offit K, Koduru PRK, Hollis R, Filippa D, Jhanwar SC, Clarkson BC, Chaganti RSK: 18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance. Br J Haematol 72:178, 1989
40. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107, 1991
41. Levy E, Brouet JC: Interleukin-10 presents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424, 1994
42. Navratil E, Gaulard P, Kanavaros P, Audouin A, Bougaran A, Martin M, Diebold J, Mason DY: Expression of the bcl-2 protein in B-cell lymphomas arising from mucosa-associated lymphoid tissue (MALT). J Clin Pathol 48:18, 1995
43. Kondo E, Nakamura S, Onoue H, Matsuo Y, Yoshino T, Aoki H, Hayashi K, Takahashi K, Minowada J, Nomura S, Akagi T: Detection of bcl-2 protein and bcl-2 messenger RNA in normal and neoplastic lymphoid tissues by immunohistochemestry and in situ hybridization. Blood 80:204, 1992
44. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5:61, 1994
45. Kramer MHH, Hermans J, Krol S, van Groningen K, van Krieken JHJM, de Jong D, Kluin P:Bcl-2 expression in diffuse large cell lymphoma. Blood 84:444a, 1994 (abstr)
46. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER, Fisher RI: Prognostic significance of the Ki-67-associated antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group Trial. Blood 83:1460, 1993
47. Jalkanen S, Joensuu H, Soderstrom K-O, Kleimi P: Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 87:1835, 1991